Opioid agonist therapy trajectories among street entrenched youth in the context of a public health crisis.
North America
Opioid agonist therapy
Opioid use disorder
Overdose
Street entrenched youth
Substance use disorder
Journal
SSM - population health
ISSN: 2352-8273
Titre abrégé: SSM Popul Health
Pays: England
ID NLM: 101678841
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
14
01
2020
revised:
27
05
2020
accepted:
01
06
2020
entrez:
3
7
2020
pubmed:
3
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
North America is in the midst of an overdose crisis that is having devastating effects among street entrenched youth (<30 years of age). Opioid agonist therapy (OAT) is a cornerstone of the public health response to this crisis; yet, we struggle to connect youth to OAT across numerous settings. This qualitative study examined perspectives on OAT among street entrenched youth and their providers in Vancouver, Canada. Our findings reveal youth's hopes and fears surrounding making a "full" recovery from past substance use. Youth often equated getting off opioids with "getting back to normal" and the ability to pursue "normal" kinds of futures. While many initiated OAT for short periods of time (<one month) to mediate the discomfort of withdrawal during in-patient treatment, adherence to medications like methadone and buprenorphine over the longer term did not fit with many youth's visions of "normal" futures. A number of polysubstance using youth did not access OAT, despite its lifesaving potential. Youth who did access OAT often preferred methadone because of its perceived ability to mediate longstanding physical and mental health issues. Participants who accessed OAT had the most success with adherence when they were invested in this treatment modality and actively involved in decision making around what kind of medication would work best for them, and for how long. In the absence of this collaboration, many youth made the decision to taper off of OAT independently, frequently resulting in relapse and heightened overdose risk.
Identifiants
pubmed: 32613075
doi: 10.1016/j.ssmph.2020.100609
pii: S2352-8273(20)30246-9
pii: 100609
pmc: PMC7317668
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100609Subventions
Organisme : NIDA NIH HHS
ID : R01 DA044181
Pays : United States
Organisme : NIDA NIH HHS
ID : R25 DA037756
Pays : United States
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Alcohol Clin Exp Res. 1995 Dec;19(6):1528-36
pubmed: 8749822
Harm Reduct J. 2006 May 24;3:18
pubmed: 16723029
J Adolesc Health. 2012 Aug;51(2):144-9
pubmed: 22824444
Cochrane Database Syst Rev. 2013 Feb 28;(2):CD003409
pubmed: 23450540
Subst Use Misuse. 2009;44(14):1979-89
pubmed: 20001689
Can J Public Health. 2005 Nov-Dec;96(6):432-7
pubmed: 16350867
Psychol Addict Behav. 2005 Mar;19(1):28-34
pubmed: 15783275
Subst Abuse Rehabil. 2016 Jul 20;7:99-105
pubmed: 27499655
Psychol Addict Behav. 2004 Jun;18(2):160-9
pubmed: 15238058
J Addict Med. 2014 May-Jun;8(3):176-82
pubmed: 24695018
J Addict Med. 2018 May/Jun;12(3):170-183
pubmed: 29432333
Arch Gen Psychiatry. 2005 Oct;62(10):1157-64
pubmed: 16203961
J Child Adolesc Psychopharmacol. 2019 Aug;29(7):487-497
pubmed: 31246496
BMJ Open. 2014 Jul 21;4(7):e005419
pubmed: 25052173
BMC Public Health. 2009 Jun 03;9:171
pubmed: 19493353
Am J Addict. 2004;13 Suppl 1:S42-66
pubmed: 15204675
J Clin Psychiatry. 2014 Aug;75(8):e785-93
pubmed: 25191915
Drug Alcohol Depend. 2016 Dec 01;169:117-127
pubmed: 27810654
N Engl J Med. 2009 Aug 20;361(8):777-86
pubmed: 19692689
Addict Sci Clin Pract. 2018 May 7;13(1):15
pubmed: 29730987
Cochrane Database Syst Rev. 2014 Jun 24;(6):CD007210
pubmed: 24957634
Subst Use Misuse. 2014 Aug;49(10):1233-40
pubmed: 24621085
Int J Drug Policy. 2016 Jan;27:23-35
pubmed: 26359046
Drug Alcohol Rev. 2011 Nov;30(6):645-51
pubmed: 21355933
J Acquir Immune Defic Syndr (1988). 1993 Sep;6(9):1049-56
pubmed: 8340896
Am J Drug Alcohol Abuse. 2008;34(6):810-20
pubmed: 19016187
Am J Addict. 2014 Jul-Aug;23(4):393-8
pubmed: 24628742
JAMA. 1965 Aug 23;193:646-50
pubmed: 14321530
Child Adolesc Psychiatr Clin N Am. 2010 Jul;19(3):609-23
pubmed: 20682224
N Engl J Med. 2003 Sep 4;349(10):949-58
pubmed: 12954743
Am J Addict. 2017 Dec;26(8):859-863
pubmed: 29143483
Lancet. 2016 Sep 24;388(10051):1260-1
pubmed: 27673455
Drug Alcohol Depend. 2009 Sep 1;104(1-2):73-7
pubmed: 19443138
J Consult Clin Psychol. 2002 Dec;70(6):1224-39
pubmed: 12472299
Drug Alcohol Depend. 1998 Nov 1;52(3):257-60
pubmed: 9839152
Addict Sci Clin Pract. 2014 Jun 18;9:10
pubmed: 24942534
N Engl J Med. 2000 Nov 2;343(18):1290-7
pubmed: 11058673
Lancet. 2003 Feb 22;361(9358):662-8
pubmed: 12606177
JAMA Psychiatry. 2016 May 1;73(5):447-55
pubmed: 27049826
JAMA. 2008 Nov 5;300(17):2003-11
pubmed: 18984887
Soc Sci Med. 2014 Jun;110:41-8
pubmed: 24721446
Harm Reduct J. 2017 Jun 5;14(1):31
pubmed: 28583136
J Public Health Policy. 2015 Aug;36(3):350-63
pubmed: 25811385
Exp Clin Psychopharmacol. 2018 Aug;26(4):403-409
pubmed: 29939049
Addict Behav. 2001 May-Jun;26(3):453-60
pubmed: 11436937
J Adolesc Health. 2017 Jun;60(6):747-750
pubmed: 28258807
Drug Alcohol Depend. 2015 Aug 1;153:135-9
pubmed: 26096535
Drug Alcohol Depend. 2007 May 11;88(2-3):313-6
pubmed: 17141427